预约演示

更新于：2026-04-02

Japanese encephalitis vaccine, inactivated(Valneva SE)

更新于：2026-04-02

概要

概要

基本信息

药物类型

灭活疫苗、预防性疫苗

别名

Ixiaro、Japanese-encephalitis vaccine (inactivated, adsorbed)、Japanese-encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells)

+ [11]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染神经系统疾病其他疾病

在研适应症

日本脑炎

非在研适应症-

原研机构

Valneva SE

在研机构

VALNEVA Austria GmbH

非在研机构-

权益机构

Vivalis SA

Bavarian Nordic A/S

Valneva SE

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2009-03-30),

日本脑炎

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的临床试验

CTRI/2023/07/055155

/ Not yet recruitingN/AIIT

Immunogenicity and safety of JENVAC and JEEV vaccines administered for prevention of Japanese encephalitis in an interchangeable dosing schedule among healthy Indian children: A multicentric, phase IV, open-labeled, randomized controlled trial - Nil

开始日期2023-11-10

申办/合作机构

Indian Council of Medical Research

NCT03971058

/ Unknown status临床4期IIT

Characterisation of Cellular and Humoral Immune Responses Following the First Booster Immunisation With the Inactivated, Purified Japanese Encephalitis Vaccine IXIARO® in Elderly Compared to Young Individuals.

The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis vaccine in elderly subjects (above 60 years of age) in comparison to a young study group.

开始日期2019-03-01

申办/合作机构

Medical University of Vienna

[+1]

NCT01559831

/ Withdrawn临床1期

Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEV09L37

IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.

开始日期2012-06-01

申办/合作机构

VALNEVA Austria GmbH

100 项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的临床结果

登录后查看更多信息

100 项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的转化医学

登录后查看更多信息

100 项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的专利（医药）

登录后查看更多信息

项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的文献（医药）

2026-03-01·REVIEWS IN MEDICAL VIROLOGY

Japanese Encephalitis: Understanding Its Impact, Prevention, and the Role of Vaccination

Review

作者: Alshammari, Thamir M. ; Khan, Zaid Z. ; Faiyazuddin, Md. ; Iftekhar, Shaikh Shoaib ; Majeed, Shaikh Shahbaz A. ; Rodriguez‐Morales, Alfonso J. ; Mehta, Rachana ; Sharma, Sakshi ; Shaikh, Mohd Sayeed ; López‐Marín, Juan Felipe ; Srivastava, Shriyansh ; Zambrano, Lysien ; Sah, Sanjit ; Mohanty, Aroop ; Imran, Syed J.

ABSTRACT:

Japanese encephalitis (JE) is a mosquito‐borne viral disease and remains an important cause of viral encephalitis in Asia and parts of the Western Pacific. Earlier WHO‐supported global burden estimates published around 2014 suggested approximately 68,000 clinical cases and up to 20,400 deaths annually; however, the World Health Organization emphasises that the true burden of JE is difficult to quantify due to substantial underreporting and heterogeneous surveillance systems. Although vaccination programs have led to marked declines in incidence in several countries, JE transmission persists in endemic regions, and sporadic outbreaks continue to occur. In the absence of specific antiviral therapy, prevention remains the cornerstone of JE control, with vaccination representing the most effective public health intervention. Among available vaccines, the live‐attenuated SA14‐14‐2 vaccine has played a central role in reducing the burden of JE in endemic countries. Its high effectiveness, long‐term protection following a single dose, favourable safety profile, WHO prequalification, and incorporation into national immunisation programs have made it the backbone of JE prevention in Asia. Inactivated vaccines, such as IXIARO, and chimaeric vaccines, such as IMOJEV, provide important complementary options, particularly for travellers and non‐endemic populations. This review synthesises current knowledge on JE epidemiology, transmission, clinical manifestations, diagnostics, pathogenesis, and advances in vaccination strategies. By integrating recent outbreak data, immunological insights, and vaccine developments, we highlight the continued public health relevance of JE and the critical importance of sustained vaccination programs, surveillance strengthening, and equitable vaccine access to further reduce its global impact.

2024-10-19·Journal of travel medicine

A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine

Article

作者: Ramljak, Irena Čorbić ; Lingnau, Karen ; Dubischar, Katrin L ; Hochreiter, Romana ; Wressnigg, Nina V ; Schneider, Martina ; Eder-Lingelbach, Susanne ; Obersriebnig, Michaela J ; Bézay, Nicole I

Abstract:

Background:

Zika virus (ZIKV) is an emerging public health threat, rendering development of a safe and effective vaccine against the virus a high priority to face this unmet medical need. Our vaccine candidate has been developed on the same platform used for the licensed vaccine IXIARO®, a vaccine against Japanese Encephalitis virus, another closely related member of the Flaviviridae family.

Methods:

Between 24 February 2018 and 16 November 2018, we conducted a randomized, observer-blinded, placebo controlled, single center phase 1 study to assess the safety and immunogenicity of an adjuvanted, inactivated, purified whole-virus Zika vaccine candidate in the USA. A total of 67 healthy flavivirus-naïve adults aged 18–49 years were randomly assigned to one of five study arms to receive two immunizations of either high dose or low dose (6 antigen units or 3 antigen units) with both dose levels applied in two different immunization regimens or placebo as control.

Results:

Our vaccine candidate showed an excellent safety profile independent of dose and vaccination regimen with predominantly mild adverse events (AEs). No serious AE has been reported. The ZIKV vaccine induced neutralizing antibodies in all tested doses and regimens with seroconversion rates up to 85.7% (high dose), which remained up to 40% (high dose) at 6 months follow-up. Of note, the rapid regimen triggered a substantial immune response within days.

Conclusions:

The rapid development and production of a ZIKV vaccine candidate building on a commercial Vero-cell manufacturing platform resulted in a safe and immunogenic vaccine suitable for further clinical development. To optimize antibody persistence, higher doses and a booster administration might be considered.

2023-10-01·The Lancet. Infectious diseases

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

Article

作者: Michael A Koren ; Gina Donofrio ; Merlin L Robb ; Paul B Keiser ; Stephen J Thomas ; Shelly J Krebs ; Justin M Curley ; Mihret F Amare ; Janice Darden ; Trevor A Crowell ; Gregory D Gromowski ; Nelson L Michael ; Richard G Jarman ; Nathanial K Copeland ; Jack N Hutter ; Tsedal Mebrahtu ; Christine Lee ; Rafael De La Barrera ; Margaret Costanzo ; Kristin T Mills ; Vincent Dussupt ; Leyi Lin ; Oluwaseun Adedeji ; Sheila Peel ; Anais Valencia-Ruiz ; Erica L Sondergaard ; Kayvon Modjarrad ; Kenneth H Eckels ; Melinda J Hamer

BACKGROUND:

Zika virus infection is a threat to at-risk populations, causing major birth defects and serious neurological complications. Development of a safe and efficacious Zika virus vaccine is, therefore, a global health priority. Assessment of heterologous flavivirus vaccination is important given co-circulation of Japanese encephalitis virus and yellow fever virus with Zika virus. We investigated the effect of priming flavivirus naive participants with a licensed flavivirus vaccine on the safety and immunogenicity of a purified inactivated Zika vaccine (ZPIV).

METHODS:

This phase 1, placebo-controlled, double-blind trial was done at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, MD, USA. Eligible participants were healthy adults aged 18-49 years, with no detectable evidence of previous flavivirus exposure (by infection or vaccination), as measured by a microneutralisation assay. Individuals with serological evidence of HIV, hepatitis B, or hepatitis C infection were excluded, as were pregnant or breastfeeding women. Participants were recruited sequentially into one of three groups (1:1:1) to receive no primer, two doses of intramuscular Japanese encephalitis virus vaccine (IXIARO), or a single dose of subcutaneous yellow fever virus vaccine (YF-VAX). Within each group, participants were randomly assigned (4:1) to receive intramuscular ZPIV or placebo. Priming vaccinations were given 72-96 days before ZPIV. ZPIV was administered either two or three times, at days 0, 28, and 196-234. The primary outcome was occurrence of solicited systemic and local adverse events along with serious adverse events and adverse events of special interest. These data were analysed in all participants receiving at least one dose of ZPIV or placebo. Secondary outcomes included measurement of neutralizing antibody responses following ZPIV vaccination in all volunteers with available post-vaccination data. This trial is registered at ClinicalTrials.gov, NCT02963909.

FINDINGS:

Between Nov 7, 2016, and Oct 30, 2018, 134 participants were assessed for eligibility. 21 did not meet inclusion criteria, 29 met exclusion criteria, and ten declined to participate. 75 participants were recruited and randomly assigned. 35 (47%) of 75 participants were male and 40 (53%) were female. 25 (33%) of 75 participants identified as Black or African American and 42 (56%) identified as White. These proportions and other baseline characteristics were similar between groups. There were no statistically significant differences in age, gender, race, or BMI between those who did and did not opt into the third dose. All participants received the planned priming IXIARO and YF-VAX vaccinations, but one participant who received YF-VAX dropped out before receipt of the first dose of ZPIV. 50 participants received a third dose of ZPIV or placebo, including 14 flavivirus-naive people, 17 people primed with Japanese encephalitis virus vaccine, and 19 participants primed with yellow fever vaccine. Vaccinations were well tolerated across groups. Pain at the injection site was the only adverse event reported more frequently in participants who received ZPIV than in those who received placebo (39 [65%] of 60 participants, 95% CI 51·6-76·9 who received ZPIV vs three [21·4%] of 14 who received placebo; 4·7-50·8; p=0·006). No patients had an adverse event of special interest or serious adverse event related to study treatment. At day 57, the flavivirus-naive volunteers had an 88% (63·6-98·5, 15 of 17) seroconversion rate (neutralising antibody titre ≥1:10) and geometric mean neutralising antibody titre (GMT) against Zika virus of 100·8 (39·7-255·7). In the Japanese encephalitis vaccine-primed group, the day 57 seroconversion rate was 31·6% (95% CI 12·6-56·6, six of 19) and GMT was 11·8 (6·1-22·8). Participants primed with YF-VAX had a seroconversion rate of 25% (95% CI 8·7-49·1, five of 20) and GMT of 6·6 (5·2-8·4). Humoral immune responses rose substantially following a third dose of ZPIV, with seroconversion rates of 100% (69·2-100; ten of ten), 92·9% (66·1-99·8; 13 of 14), and 60% (32·2-83·7, nine of 15) and GMTs of 511·5 (177·6-1473·6), 174·2 (51·6-587·6), and 79 (19·0-326·8) in the flavivirus naive, Japanese encephalitis vaccine-primed, and yellow fever vaccine-primed groups, respectively.

INTERPRETATION:

We found ZPIV to be well tolerated in flavivirus naive and primed adults but that immunogenicity varied significantly according to antecedent flavivirus vaccination status. Immune bias towards the flavivirus antigen of initial exposure and the timing of vaccination may have impacted responses. A third ZPIV dose overcame much, but not all, of the discrepancy in immunogenicity. The results of this phase 1 clinical trial have implications for further evaluation of ZPIV's immunisation schedule and use of concomitant vaccinations.

FUNDING:

Department of Defense, Defense Health Agency; National Institute of Allergy and Infectious Diseases; and Division of Microbiology and Infectious Disease.

项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的新闻（医药）

2026-03-18

·BioSpace

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reduction in operating cash burn 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year Lyon (France), March 18, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its audited consolidated financial results for the year ended December 31, 2025, provided corporate updates and confirmed its financial guidance for 2026 1 . The Company also announced the filing of its annual report on Form 20-F and Universal registration document (URD) for the financial year ended December 31, 2025 with the U.S. Securities and Exchange Commission (SEC) and the French financial market authority (Autorité des marchés financiers or AMF), respectively. The full-year 2025 consolidated financial results are available on the Company’s website ( Financial Reports – Valneva ) 2 . Valneva will provide a live webcast of its full-year 2025 results conference call beginning at 3 p.m. CET/10 a.m. EDT today. This webcast will also be available on the Company’s website. Please refer to this link: 2025 Financial Performance Total revenues of €174.7 million, up from €169.6 million in 2024, including the recognition of variable consideration relating to the Company’s research collaboration and licensing agreement for the Lyme disease program Product sales of €157.9 million, compared to €163.3 million in 2024, reflecting the planned wind-down of third-party sales (-42.3% versus 2024). Proprietary product sales increased by 9% at constant exchange rate (CER) 3 Net loss amounted to €115.2 million compared to a net loss of €12.2 million in 2024, while the prior year amount benefited from a €90.8 million net gain related to the sale of the Priority Review Voucher (PRV) received for IXCHIQ ® Operating cash burn continued to decline, improving to €52.9 million in 2025 compared to €67.2 million in 2024 and €202.7 million in 2023 Reiterated 2026 Outlook and Financial Guidance First Phase 3 data readout for Lyme disease vaccine candidate (VLA15) anticipated in the first half of 2026, with regulatory submissions expected to follow as planned by Pfizer, subject to positive results If approved, VLA15 will be the fourth vaccine successfully developed by Valneva and subsequent commercialization by Pfizer would enable Valneva to further expand and accelerate its pipeline of innovative vaccines in line with the Company’s strategic vision First Phase 2 data for tetravalent Shigella vaccine candidate S4V2 are expected mid-2026, with a decision on subsequent development steps in the second half of 2026 Further enhancement of the Company’s R&D pipeline with differentiated vaccine candidates addressing areas of high unmet medical need Total revenues for full-year 2026 are expected to range between €155 million and 170 million, including product sales between €145-160 million The lower product sales guidance in 2026 versus the prior year reflects continued growth of established commercial brands, offset by the planned wind-down of third-party sales, as previously guided. Disciplined cash management will remain a priority, with operating cash burn expected to decline further in 2026, while continuing to support strategic R&D investments Peter Bühler, Valneva’s Chief Financial Officer , commented, “We are approaching the potentially transformative Phase 3 data readout for our Lyme disease vaccine candidate, an inflection point that could significantly shape our Company’s future and strengthen our long‑term strategy. While 2025 tested our resilience, it also underscored the strength of our team’s disciplined execution. In 2026, we remain firmly committed to prudent capital allocation to support sustainable growth and advance our strategic vision.” Financial Information € in million 12 months ended December 31, 2025 2024 Total revenues 174.7 169.6 Product sales 157.9 163.3 Net profit/(loss) (115.2) (12.2) Adjusted EBITDA 4 (59.4) 32.9 Cash 109.7 168.3 Commercial Portfolio Valneva’s commercial portfolio comprises three vaccines, IXIARO ® /JESPECT ® , DUKORAL ® and IXCHIQ ® . The Company’s main third‑party product distribution contract concluded in 2025 and this activity is now expected to naturally wind down, as previously communicated. Valneva’s total product sales in 2025 were €157.9 million compared to €163.3 million in 2024, reflecting a 42.3% planned reduction in third party product sales (€19.2 million in 2025 versus €33.2 million in 2024). Excluding third-party sales, total product sales increased by 9% at CER. JAPANESE ENCEPHALITIS VACCINE IXIARO ® /JESPECT ® In 2025, IXIARO ® /JESPECT ® sales increased by 4.6% to €98.4 million, resulting from growth in the traveler’s market. This compares with 2024, when IXIARO ® sales were impacted by supply constraints. Sales at CER grew by 7.2% compared to 2025. In January 2025, Valneva secured a new $32.8 million contract with the United States Department of Defense (DoD) 5 . CHOL ERA / ETEC 6 -DIARRHEA VACCINE DUKORAL ® In 2025, DUKORAL ® sales were €31.9 million as compared to €32.3 million in 2024. Sales in 2025 were notably affected by €1.0 million of adverse currency effects, as well as lower sales in Germany due to the gradual transition of distribution to CSL Seqirus. Sales at CER grew by 1.8%. CHIKUNGUNYA VACCINE IXCHIQ ® In 2025, Valneva reported IXCHIQ ® sales of €8.4 million, compared to €3.7 million in 2024. Sales in 2025 benefited from the vaccine’s launch in several European countries, including the supply of doses to help contain a major chikungunya outbreak on the French island of La Réunion. This growth was partly offset by the previously communicated label and user‑restriction constraints 7 . In January 2026, Valneva voluntarily withdrew the Biologics License Application (BLA) and Investigational New Drug (IND) application for IXCHIQ ® in the United States. The Company remains focused on expanding IXCHIQ ® access and sales in other territories, including Low- and Middle-Income Countries (LMICs), where medical need remains high. Clinical Vaccine Programs LYME DISEASE VACCINE CANDIDATE – VLA15 VALOR Phase 3 Results expected in the first half of 2026 Valneva and Pfizer are developing VLA15, a vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease. VLA15 is the most advanced Lyme disease vaccine candidate currently in clinical development, with two Phase 3 trials underway. It leverages an established mechanism of action, inducing antibodies to Borrelia outer surface protein A (OspA) to prevent the transmission of Lyme borreliosis from infected ticks. The vaccine antigens are designed to target the six most prevalent Borrelia serotypes. Pfizer is conducting a randomized, placebo-controlled Phase 3 field efficacy trial, VALOR (Vaccine Against Lyme for Outdoor Recreationists). Phase 3 vaccinations were completed in 2025 and VALOR trial results are expected to be reported in the first half of 2026. Subject to positive Phase 3 results, Pfizer intends to submit a Biologics License Application (BLA) to the U.S. FDA and Marketing Authorization Application (MAA) to the European Medicines Agency in 2026. Upon approval and successful commercialization of VLA15, Valneva would be eligible to receive $143 million in initial milestone payments from Pfizer, plus sales royalties ranging from 14% to 22% and up to $100 million in cumulative sales milestones. CHIKUNGUNYA VACCINE - IXCHIQ ® / VLA1553 Pilot vaccination campaign ongoing in Brazil In February 2026, Valneva and Instituto Butantan announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva’s single-shot chikungunya vaccine, IXCHIQ ® . The vaccination campaign will serve as the basis for post-marketing commitment studies evaluating the effectiveness and safety of IXCHIQ ® in a real-world setting and generating real-world evidence in a large population. The PVS, agreed to between the Brazilian Ministry of Health (MoH) and Instituto Butantan, will be implemented in ten Brazilian municipalities strategically selected based on epidemiological and operational criteria in support of the PVS. In line with the current IXCHIQ ® label in Brazil, adults aged 18 to 59 years will be invited to participate, with the objective of achieving 20% to 40% vaccine coverage within the target population. Additionally, Valneva, through its partner Instituto Butantan, will donate up to 500,000 doses of IXCHIQ ® to the Brazilian MoH, for use in the program. SHIGELLA VACCINE CANDIDATE – S4V2 First Phase 2 results expected mid-2026 S4V2 is the world’s most clinically advanced tetravalent vaccine candidate against shigellosis, the second leading cause of fatal diarrhea worldwide. Two clinical trials of S4V2, a Phase 2 infant safety and immunogenicity trial 8 , and a Phase 2b Human Challenge trial (CHIM) 9 , sponsored by LimmaTech Biologics AG, are ongoing. First Phase 2 results are expected mid-2026. Subject to positive results for both trials, Valneva will assume responsibility for all further development 10 . No approved multivalent Shigella vaccine is currently available outside of Russia or China, and the development of Shigella vaccines has been identified as a priority by the World Health Organization (WHO) 11 . In October 2024, the U.S. FDA granted Fast Track designation to S4V2, recognizing its potential to address a serious condition and fill an unmet medical need 12 . The global market opportunity for a vaccine against Shigella is estimated to exceed $500 million annually 13 . ZIKA VACCINE CANDIDATE – VLA1601 Positive Phase 1 results announced In 2025, Valneva announced positive safety and immunogenicity results for the Phase 1 clinical trial of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV) 14 . Despite the medical need, regulatory pathways and market opportunity for potential Zika vaccines remain uncertain. Valneva will therefore only consider further potential development steps for VLA1601 if private and public funding opportunities materialize. Full Year 2025 Financial Review (Audited 15 , consolidated under IFRS) Revenues Valneva’s total revenues were €174.7 million in 2025 as compared to €169.6 million in 2024. The increase was driven by IXIARO ® /JESPECT ® and IXCHIQ ® sales. Other revenues, including revenues from collaborations, licensing and services increased to €16.8 million in 2025 as compared to €6.3 million in 2024. The increase for 2025 was mainly attributable to the recognition of variable consideration relating to the Company’s research collaboration and licensing agreement for the Lyme disease program. Operating Result and adjusted EBITDA Costs of goods and services sold (COGS) were €107.1 million in 2025. The gross margin on commercial product sales, excluding IXCHIQ ® , remained flat at 50.8% as compared to 50.6% in 2024. Positive effects from lower third-party product sales were offset by higher manufacturing expenditure following the completion of the manufacturing transfer to the new Almeida facility in Scotland. Gross margin for IXIARO ® reached 59.6%, slightly lower than the 61.0% achieved in 2024. The decline for 2025 was mainly driven by higher manufacturing costs at the Almeida facility combined with lower manufacturing volumes during 2025. Gross margin for DUKORAL ® reached 33.3% for 2025 as compared to 38.7% in 2024. Batch failures during the last quarter of 2025 were the primary factor behind this margin compression. Gross margin for IXCHIQ ® was negative, impacted by €8.5 million of inventory write-offs, mostly related to the termination of the supply agreement with Serum Institute of India in December 2025. Finally, COGS of €12.5 million were attributable to the third-party distribution business, €10.8 million related to idle capacity and costs not allocated to products and €7.2 million related to services. For comparison, total COGS in 2024 were €98.5 million, including €90.0 million in cost of goods and €8.5 million in cost of services. Research and development expenses amounted to €85.3 million in 2025, compared to €74.1 million in 2024. This increase for 2025 was mainly driven by higher costs related to the Shigella vaccine under the R&D collaboration agreement with LimmaTech Biologics AG and increased IXCHIQ ® post-marketing obligations. Marketing and distribution totaled €37.4 million in 2025, down from €52.4 million in 2024. The decrease for 2025 primarily reflects reduced advertising and promotional spending related to IXCHIQ ® , partly offset by higher warehousing and distribution costs. General and administrative expenses decreased to €37.3 million in 2025 from €42.8 million in 2024. The reduction for 2025 was primarily driven by lower recruiting costs, reduced insurance charges, and savings in advisory and professional services. Other income, net of other expenses, decreased to €10.4 million in 2025 from €20.7 million in 2024. The decline for 2025 was mainly driven by lower R&D tax credits in Austria and reduced grant income from Scottish Enterprise recognized during 2025. Valneva recorded an operating loss of €82.1 million in 2025 compared to an operating profit of €13.3 million in 2024. This change was primarily driven by the absence of the 2024 net gain of €90.8 million related to the PRV sale. The adjusted EBITDA loss (as defined below) in 2025 was €59.4 million, compared to an adjusted EBITDA profit of €32.9 million in 2024, which in 2024 had benefited from the gain associated with the PRV sale. Net Result Valneva recorded a net loss of €115.2 million in 2025, compared to a net loss of €12.2 million in 2024. Net result, operating loss and adjusted EBITDA are not comparable between 2024 and 2025 because of the 2024 gain from the PRV sale. Finance expense and currency effects resulted in a net finance expense of €32.1 million in 2025, compared to €24.8 million in 2024. This increase was mainly attributable to €17.9 million higher interest expenses, mostly related to one-time effects from the 2025 repayment of the loan with Deerfield Management Company and OrbiMed (D&O). Cash Flow and Liquidity Net cash used in operating activities amounted to €52.9 million in 2025, compared to €67.2 million in 2024. The reduction in 2025 was driven by efficient cost management. Cash used in investing activities amounted to €1.7 million in 2025, compared to cash inflows of €76.9 million in 2024. The 2025 outflows were primarily related to purchases of equipment, partly offset by interest income. In 2024, investing cash inflows were driven by €90.8 million in net proceeds from the sale of the PRV. Net cash used in financing activities amounted to €0.6 million in 2025, compared to a net cash inflow of €30.7 million in 2024. Financing cash inflows in 2025 included €27.4 million in net proceeds mainly related to transactions using the Company’s at-the-market facility program, largely offset by interest payments and one-time effects related to the repayment of the D&O loan. Cash inflows for 2024 included €57.1 million in proceeds from a private placement. Cash and cash equivalents were €109.7 million as at December 31, 2025, compared to €168.3 million as at December 31, 2024. Non-IFRS Financial Measures Management uses and presents IFRS results as well as the non-IFRS measure of Adjusted EBITDA to evaluate and communicate its performance. While non-IFRS measures should not be construed as alternatives to IFRS measures, management believes non-IFRS measures are useful to further understand Valneva’s current performance, performance trends, and financial condition. Adjusted EBITDA is a common supplemental measure of performance used by investors and financial analysts. Management believes this measure provides additional analytical tools. Adjusted EBITDA is defined as earnings/loss for the period before income tax, finance (income)/expense, foreign exchange (gain)/loss, amortization, depreciation, and impairment. A reconciliation of Adjusted EBITDA to net loss for the period, which is the most directly comparable IFRS measure, is set forth below: € in million Twelve months ended December 31 (consolidated per IFRS) 2025 2024 Loss for the period (115.2) (12.2) Add: Income tax expense 1.1 0.8 Total Finance income (2.6) (2.4) Total Finance expense 41.9 24.0 Foreign exchange (gain)/loss – net (7.2) 3.2 Result from investments in associates - - Amortization 4.8 4.9 Depreciation 16.9 14.7 Impairment 0.9 0.0 Adjusted EBITDA (59.4) 32.9 Product sales (excluding third-party sales) at constant exchange rate: References to changes in net sales at constant exchange rate (CER) indicate that currency fluctuation effects have been removed. Net sales for the period in question are recalculated using the exchange rates applied in the prior period, as detailed below. € in million Twelve months ended December 31 (unaudited results, consolidated per IFRS) 2025 2024 Year-over-year growth % Product sales 157.9 163.3 - 3.3% Third-party product sales 19.2 33.2 - 42.3% Product sales excluding third-party sales 138.7 130.1 + 6.7% Effect of exchange rates (excluding third-party sales) 3.1 - Product sales (excluding third-party sales) at constant exchange rates (CER) 141.8 - + 9.0% Availability of the Full Year 2025 Financial Reports The URD and 20-F are available on the Valneva website here . In addition, the URD and 20-F are available on the AMF website ( ) and SEC website ( ), respectively. The Company’s 2025 URD includes its 2025 annual financial report, annual management report, sustainability report and the Board of Directors’ corporate governance report. The 2025 URD and 20‑F also provide a description of the Company’s major agreements, including the Company’s exclusive license agreement for Valneva’s Clostridioides difficile vaccine candidate, VLA84, with the Austrian biotechnology company Elaris, who is developing a next-generation vaccine. This agreement includes two development‑related milestone payments as well as multiple milestone payments tied to regulatory approval and commercialization. Additionally, the URD and 20-F describe the FDA’s recent inspection of the Company’s Almeida manufacturing facility in Scotland. The Company has received a response letter from the FDA, indicating that the FDA is unable to grant approval of the Almeida facility for the manufacturing of IXIARO ® . The Company is actively addressing the FDA’s observations to remediate the issues identified. In the meantime, the Almeida facility is approved by the European Medicines Agency and Health Canada and operates under a manufacturers license from the UK’s Medicines and Healthcare products Regulatory Agency. Therefore, IXIARO ® doses produced at this facility will be sold in these regions while products manufactured at the Manson site will be distributed in the United States. About Valneva SE We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at . Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelotfontaine@valneva.com Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in France. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements with respect to: future financial performance and financial guidance including projected product sales, total revenue and total R&D investments; Valneva’s plans for investment in future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of Valneva’s product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of Valneva’s commercial products and product candidates; and potential growth opportunities and trends, including the assumptions and expectations regarding total market opportunity targeted by Valneva’s product candidates and commercial products. These forward-looking statements are based on Valneva’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Valneva’s business, strategy, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: Valneva’s success in the commercialization of its commercial products; uncertainties and delays involved in the development and manufacture of vaccines; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on Valneva’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Valneva’s ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; the impact of the global and European credit crisis; the ability to obtain or maintain patent or other proprietary intellectual property protection and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in Valneva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) and the Autorité des marchés financiers (“AMF”) on March 18, 2026, and in other filings made with the SEC and AMF from time to time. Valneva is providing this information as of the date of this press release and expressly disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. 1 Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook - Valneva 2 The audit procedures on the consolidated financial statements have been performed. The audit report will be issued upon finalization of audit procedures regarding the URD filing. 3 Changes in product sales are presented at constant exchange rate (CER), where indicated. For additional information regarding CER, please see “Product sales (excluding third-party sales) at constant exchange rate” section later 4 For additional information on Adjusted EBITDA, please refer to the “Non-IFRS Financial Measures” section at the end of the PR 5 Valneva Announces New IXIARO ® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Valneva 6 Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium. 7 Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ ® In the U.S. ; Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ ® in Elderly ; Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers 8 Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 - Valneva 9 Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 10 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate - Valneva 11 Immunization, Vaccines and Biologicals (who.int) 12 Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V - Valneva 13 LEK analysis 14 15 The audit procedures on the consolidated financial statements have been performed. The audit report will be issued upon finalization of audit procedures regarding the URD filing. Attachment 2026_03_18_FY_2025_Results_PR_EN_Final

临床2期临床3期临床结果疫苗临床1期

2026-02-19

·Pharmaceutical Technology

Valneva’s Lyme disease vaccine offers beacon of hope amid 2025 sales dip

Valneva’s commercial portfolio is made up of three travel vaccines. Credit: mundissima/Shutterstock.com Valneva reported a drop in product sales in 2025 amid market restrictions for chikungunya vaccine Ixchiq, with the travel vaccine specialist betting on upcoming readouts to turn the business’ growth around. As per preliminary results, Valneva’s product sales reached €157.9m ($186.1m) in 2025, a 3.3% drop from €163.3m in 2024. The company’s commercial products include Japanese encephalitis vaccine Ixiaro and cholera vaccine Dukoral, but its lead brand is Ixchiq. Ixchiq has endured a difficult regulatory spell over the past year. In August 2025, the US Food and Drug Administration (FDA) suspended Ixchiq’s license due to “serious safety concerns”. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) followed suit in February 2026 for the same reasons. The vaccine had been temporarily suspended in people over 65 years of age in the UK in June 2025. While Valneva did not reveal Ixchiq’s sales numbers for 2025, the company said the total product sales downturn was “expected”. The segment that dragged growth was third-party sales, which decreased 42.3% – though this contributed €19.2m to the €157.9m. Despite its products not tracking well, Valneva’s total revenue increased to €174.7m in 2025, up from €169.6m in 2024. The company added that this was buoyed by the ongoing research collaboration and licensing agreement for the Lyme disease programme with Pfizer. In April 2020, Pfizer began working with Valneva to help develop the latter’s Lyme disease vaccine candidate, which was in Phase II trials at the time. Valneva expects the first Phase III (NCT05477524) data readout for the candidate, dubbed VLA15, in the first half of 2026. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence VLA15 could represent an avenue back to more positive financial results for Valneva. There is currently no approved vaccine available for the disease that is caused by a bacterial infection transmitted by infected tick bites. Recent estimates by the US Centers for Disease Control and Prevention (CDC) suggest that approximately 476,000 people may be diagnosed and treated for Lyme disease each year in the US. “VLA15’s successful commercialisation by Pfizer would enable Valneva to further expand and accelerate a pipeline of innovative vaccines in line with its strategic vision,” Valneva said in a statement. Valneva also plans to report the first Phase II data for tetravalent shigella vaccine candidate S4V2 in 2026. In-licensed from LimmaTech Biologics AG, Valneva will make a decision on the next steps of development for the jab in the second half of 2026. While shareholders prepare for pipeline updates this year, they could be set for another financially lukewarm year for Valneva. The company said it expects 2026 total revenues of between €155-170m – the higher end of this forecast would still represent a near $5m drop from 2025’s figure. Peter Bühler, Valneva’s chief financial officer, commented: “2025 challenged our resilience while reaffirming the strength of our team’s disciplined execution. We remained committed to growing our commercial brands and made strong progress across our key R&D programmes, despite headwinds around Ixchiq and the broader geopolitical pressures. As we enter 2026, we look forward to the potentially transformative Phase III data readout for our Lyme disease vaccine candidate, while remaining focused on prudent capital allocation, to support shaping and growing our business in line with our strategic vision.” Valneva is not the only company to struggle with sales growth amid a US vaccine landscape that has undergone volatility in the past year. Moderna also reported declining vaccine sales in its Q3 results, leading to a trim in its 2025 guidance. Health Secretary Robert F Kennedy (RFK) Jr has implemented policies to reduce reliance on vaccines for respiratory diseases, though there has been a knock on effect to the travel vaccine sector.

疫苗临床2期引进/卖出临床3期

2025-02-18

·GlobeNewswire-Health Care

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), February 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2024 revenue and cash results1 and provided a 2025 outlook. The Company will publish its 2024 audited consolidated financial statements and host an analyst call on March 20, 2025. 2024 Performance Total revenues were €169.6 million for the year ended December 31, 2024 compared to €153.7 million in the year ended December 31, 2023, an increase of 10%Product sales revenue reached €163.3 million for the year ended December 31, 2024 compared to €144.6 million in the same period of 2023, an increase of 13%Cash and cash equivalents were €168.3 million as at December 31, 2024, compared to €126.1 million at December 31, 2023. Year-end cash of €168.3 million, significantly augmented by the sale of the Priority Review Voucher2 and successful Private Placement3 2025 Financial Outlook Sales revenues expected to grow to €170-180 million, driving positive cash-flows for the overall commercial businessTotal revenues expected to reach €180-190 millionTotal R&D investments expected between €90 - €100 million, which will be partially offset by grant funding and anticipated R&D tax creditsContinued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; substantially lower operating cash burn expected in 2025, less than 30 million compared to over €60.0 million in 2024 Peter Bühler, Valneva’s Chief Financial Officer, commented, “Once again, we successfully delivered double digit sales growth, despite lower than anticipated launch-year IXCHIQ® sales in the U.S. We made significant clinical and regulatory progress last year, setting the stage for several important catalysts to drive value in 2025, most notably with the first Phase 3 study results for our lead Lyme disease vaccine candidate, VLA15. In 2025, we will continue to focus on commercial execution while investing strategically in advancing our science-driven pipeline to generate substantial future value. With over €168 million of cash at the end of 2024, we are entering 2025 in a good financial position to support these objectives.” Regulatory, R&D and Strategic Highlights Continued to progress Lyme disease program according to plan, including completion of primary vaccination in ongoing Phase 3 study, reporting of further positive Phase 2 booster results, and publication of Phase 2 data in the LancetSecured three additional regulatory approvals for world’s first chikungunya vaccine, IXCHIQ® (Canada, Europe, UK); filed adolescent label extension submissions; awarded new $41.3 million grant from the Coalition for Epidemic Preparedness (CEPI)4Augmented clinical pipeline with a leading tetravalent Shigella vaccine candidate5 and initiated Phase 2b trial; Granted Fast Track Designation by the United States Food and Drug Administration (FDA) Advanced novel Zika vaccine candidate into Phase 1 clinical development Finalized new $32.8 million IXIARO® supply contract with the U.S. Department of Defense in January 20256 Key Upcoming Catalysts: Lyme disease Phase 3 first data readout by the end of 2025Further chikungunya vaccine approvals, including the first endemic country (Brazil) and adolescent label extensions for IXCHIQ® in major travel marketsInitiation of Phase 3 pediatric trial of IXCHIQ® to support further potential label expansionPhase 2b efficacy data from Human Challenge Study (CHIM) of tetravalent Shigella vaccine candidate in mid-2025 and launch of pediatric studyPhase 1 results for Zika vaccine candidate in the first half of 2025 About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first chikungunya vaccine, as well as certain third-party vaccines.Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at www.valneva.com. Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP, Global Communications and European Investor RelationsM +33 (0)6 4516 7099investors@valneva.com Joshua Drumm, Ph.D.VP, Global Investor Relations M +001 917 815 4520joshua.drumm@valneva.com Forward-Looking Statements This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of technology transfer and regulatory approvals in additional markets. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 1 The financial figures presented in this release are preliminary and unaudited. The final audited financial results, which remain subject to approval by the Board of Directors, are expected to be published on March 20.2 Valneva Announces Sale of Priority Review Voucher for $103 Million - Valneva3 Valneva Announces the Success of its Private Placement Raising approximately €60 Million - Valneva4 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine - Valneva5 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate - Valneva6 Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Valneva Attachment 2025_02_18_FY2024_RevCash_PR_EN_Final

临床3期疫苗临床结果财报临床2期

100 项与 Japanese encephalitis vaccine, inactivated(Valneva SE) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BA02	DB10769

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
日本脑炎	美国	VALNEVA Austria GmbH	2009-03-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑炎	临床3期	美国	VALNEVA Austria GmbH	2010-01-01
脑炎	临床3期	澳大利亚	VALNEVA Austria GmbH	2010-01-01
脑炎	临床3期	丹麦	VALNEVA Austria GmbH	2010-01-01
脑炎	临床3期	德国	VALNEVA Austria GmbH	2010-01-01
脑炎	临床3期	瑞典	VALNEVA Austria GmbH	2010-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01246479 (Pubmed \| Travel Med Infect Dis)	临床3期	-	23	IXIARO® Japanese encephalitis vaccine	積範網蓋鏇鏇窪獵觸膚(繭淵製醖鏇網顧艱鹹範) = 襯鏇廠齋衊網獵鏇觸蓋簾糧膚網艱繭膚壓鬱鏇 (襯築艱獵廠網選餘糧觸 )	-	2020-03-07
NCT01656200 (CTgov)	临床4期	日本脑炎	17	Live attenuated Japanese encephalitis vaccine SA14-14-2	醖積廠積鬱廠網糧鏇積(糧遞廠壓壓顧蓋艱襯製) = 鹽鏇餘艱遞糧製壓夢觸壓醖鹽鬱顧鹹願夢壓顧 (簾淵鏇膚襯廠選憲觸築, 壓製鏇鬱鹹醖繭積襯蓋 ~ 憲築簾夢顧憲膚鏇構觸) 更多	-	2019-04-26
NCT01246479 (CTgov)	临床3期	日本脑炎	23	Blood draw+IC51 has given in the parent study IC51-322	遞鏇壓獵簾壓範蓋鹹繭 = 鹹構構壓遞夢遞觸製蓋壓選範積蓋顧鏇願鏇製 (簾壓築窪鬱簾齋觸獵遞, 網選醖襯壓壓遞襯鑰淵 ~ 淵襯齋鑰築廠艱範鹹積) 更多	-	2015-04-29
NCT01296360 (CTgov)	临床3期	日本脑炎	300	IXIARO (>14 Months to <2 Years)	遞廠衊廠簾醖網齋選餘 = 餘觸壓糧壓繭選範構壓鹽鹽顧壓襯積蓋鑰遞鹽 (醖顧餘壓廠淵夢膚繭艱, 夢糧製夢廠餘壓壓獵醖 ~ 遞艱襯網艱廠膚膚窪繭)	-	2014-12-19
				IXIARO (>3 Years - <18 Years)	遞廠衊廠簾醖網齋選餘 = 願夢淵艱膚齋淵齋廠鹽鹽鹽顧壓襯積蓋鑰遞鹽 (醖顧餘壓廠淵夢膚繭艱, 觸襯鏇憲構鏇衊夢繭鏇 ~ 壓鑰範獵築夢鬱鹹夢衊)
NCT01047839 (CTgov)	临床3期	脑炎	100	IC51 (>=2 Months to <3 Years)	鹹糧鹹餘蓋遞齋廠膚膚 = 襯醖顧鬱糧獵範簾衊繭觸築獵選餘鑰鏇廠鏇積 (鹽範蓋廠鏇構糧蓋鬱製, 淵膚獵艱膚廠顧艱範積 ~ 鏇廠淵築願鑰淵製簾壓) 更多	-	2014-12-19
				IC51 (>=3 to <12 Years)	鹹糧鹹餘蓋遞齋廠膚膚 = 廠鏇鹽艱窪襯齋繭積鬱觸築獵選餘鑰鏇廠鏇積 (鹽範蓋廠鏇構糧蓋鬱製, 積簾構膚憲構鏇餘鏇餘 ~ 選獵構構餘構願廠積獵) 更多
NCT00595270 (CTgov)	临床3期	日本脑炎	349	IC51 (IC51 2 x 6 µg)	壓選醖顧製願蓋糧鏇獵 = 願鹹積選壓鹹網築鹽醖構鏇遞鹹網衊觸選鑰鹹 (餘醖鹽蓋膚鑰襯範蓋夢, 願範壓鹽觸醖築糧蓋觸 ~ 選範壓鑰衊襯積鏇夢網) 更多	-	2014-03-07
				IC51 (IC51 1 x 12 µg)	壓選醖顧製願蓋糧鏇獵 = 鹽壓蓋選積壓鬱鏇窪鹹構鏇遞鹹網衊觸選鑰鹹 (餘醖鹽蓋膚鑰襯範蓋夢, 構遞襯襯蓋膚醖窪願憲 ~ 網鹹窪襯淵廠廠鑰艱顧) 更多
NCT01041573 (CTgov)	临床3期	脑炎	1,869	Havrix®720 (Havrix 720)	醖廠構遞襯艱顧糧選築 = 蓋範齋餘醖齋鬱壓築繭糧憲製簾繭鏇網廠憲遞 (願襯鑰鹽膚鏇廠蓋積憲, 獵壓壓製壓選醖醖範簾 ~ 繭醖醖艱憲選醖觸網繭) 更多	-	2014-02-27
				Prevnar (Prevnar)	醖廠構遞襯艱顧糧選築 = 憲鏇簾壓廠糧鬱選鏇夢糧憲製簾繭鏇網廠憲遞 (願襯鑰鹽膚鏇廠蓋積憲, 繭膚選醖顧膚繭窪淵繭 ~ 淵鬱繭積襯範鑰築窪窪) 更多
NCT00776230 (CTgov)	临床3期	日本脑炎	304	IC51 (IC51 Cohort 1)	繭壓蓋鹽觸鬱憲餘鏇鬱(選膚壓壓築艱衊範齋獵) = 膚簾觸選窪製繭積糧膚鬱製繭蓋蓋鹹選鬱觸範 (壓願願夢窪鑰構餘構製, 窪衊窪襯簾構積顧醖醖 ~ 淵壓夢範醖鹹淵簾構觸) 更多	-	2014-01-23
				IC51 (IC51 Cohort 2)	繭壓蓋鹽觸鬱憲餘鏇鬱(選膚壓壓築艱衊範齋獵) = 繭衊憲窪鬱鏇網獵遞積鬱製繭蓋蓋鹹選鬱觸範 (壓願願夢窪鑰構餘構製, 廠簾襯顧鬱齋淵積艱齋 ~ 顧壓範構製觸鏇艱夢鏇) 更多
NCT00594958 (CTgov)	临床3期	日本脑炎	639	IC51 (IC51 Group A)	窪鬱簾憲構艱鬱顧膚齋(蓋範餘網簾壓淵選鹽簾) = 簾蓋遞壓築鏇廠襯築醖選獵醖獵顧選積鏇襯窪 (鏇壓淵製繭衊齋廠繭網, 廠鬱齋憲構鏇鹹選願製 ~ 積廠艱遞鑰鏇醖構積積) 更多	-	2014-01-23
				IC51 (IC51 Group B)	窪鬱簾憲構艱鬱顧膚齋(蓋範餘網簾壓淵選鹽簾) = 膚齋襯壓憲窪構鏇憲壓選獵醖獵顧選積鏇襯窪 (鏇壓淵製繭衊齋廠繭網, 蓋鹹獵襯襯築製夢糧憲 ~ 艱夢鹽壓醖餘淵鬱夢蓋) 更多
NCT00604708 (CTgov)	临床3期	日本脑炎	867	IC51 (IC51)	願餘鑰蓋窪膚憲壓窪鑰 = 鑰遞艱鬱願築淵鏇範觸鏇衊醖膚築鏇鹹憲憲繭 (遞繭淵鑰鏇壓範鏇餘襯, 鏇廠艱廠觸窪獵網遞獵 ~ 築窪廠糧鑰繭壓糧糧壓) 更多	-	2012-11-29
				JE-VAX (JE-VAX)	願餘鑰蓋窪膚憲壓窪鑰 = 選憲淵艱廠繭築鑰窪艱鏇衊醖膚築鏇鹹憲憲繭 (遞繭淵鑰鏇壓範鏇餘襯, 糧艱願鹹衊鏇鑰觸獵衊 ~ 網獵襯積積齋淵衊憲鹽) 更多